CA Patent

CA3071315A1 — Dual mode radiotracer and -therapeutics

Assigned to Technische Universitaet Muenchen · Expires 2019-01-31 · 7y expired

What this patent protects

The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties:(a)one or more ligands which are capable of binding to a disease-relevant target molecule, (b)a silicon-fluoride acceptor (SIFA) moiety which compris…

USPTO Abstract

The present invention relates to a ligand-SIFA-chelator conjugate, comprising, within in a single molecule three separate moieties:(a)one or more ligands which are capable of binding to a disease-relevant target molecule, (b)a silicon-fluoride acceptor (SIFA) moiety which comprises a covalent bond between a silicon atom and a fluorine atom, and(c)one or more chelating groups, optionally containing a chelated nonradioactive or radioactive cation.

Drugs covered by this patent

Patent Metadata

Patent number
CA3071315A1
Jurisdiction
CA
Classification
—
Expires
2019-01-31
Drug substance claim
No
Drug product claim
No
Assignee
Technische Universitaet Muenchen
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.